177Lu-DOTA-EB-FAPI radionuclide therapy
XMFHIIT-2023KY037
Phase 2 small_molecule completed
Quick answer
177Lu-DOTA-EB-FAPI radionuclide therapy for Refractory Solid Tumor is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Refractory Solid Tumor
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed